Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

Keywords

Niacin, Medicine, Discontinuation, Placebo, Myocardial infarction

References

• Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis.H. M. Marvin — 1964
• Cardiac surgery and bacterial endocarditis.ChatrchaiWatan Akunakorn — 1969
• Effect of combined clofibrate--nicotinic acid treatment in ischemic heart disease.G. Rosenhamer, Lars A. Carlson — 1980
• Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid.Lars A. Carlson, M Danielson, Ingvar Ekberg — 1977
• Asymptotically Efficient Rank Invariant Test ProceduresRichard Peto, Julian Peto — 1972
• Estimation of the T-year survival rate from follow-up studies over a limited period of time.Littell As — 1952
• Clofibrate and niacin in coronary heart disease.J. Stamler — 1975
• The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group.J. Stamler — 1972
• Statistical methods for rates and proportionsT. F. de C. Marshall, J. L. Fleiss — 1973
• Applied Regression AnalysisNathan Jaspen, Norman R. Draper, Harry Smith — 1968
• Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project.&NA; — 1980
• The Coronary Drug Project: Design, Methods, and Baseline ResultsTHE CORONARY DRUG PROJECT RESEARCH GROUP — 1973
• The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group.1973
• The Coronary Drug Project. Initial findings leading to modifications of its research protocol.1970
• The Coronary Drug Project: methods and lessons of a multicenter clinical trial. Coronary Drug Project Research Group.1983
• The Coronary Drug Project1973
• Estrogens and cancer1978
• The Coronary Drug Project1970
• Estrogen and cancer) (Letter)Ziel Hk — 1972
• The U.S. Veterans Administration Cardiology Drug-Lipid Study: An Interim ReportH. Schoch — 1969

Cited by

• Prevention and regression of atherosclerosis with drug therapyQuim Casas — 1991
• Prevention of Cardiovascular Risk in Women: A New Concern for the Obstetrician/GynecologistА. И. Шабаев, Н. М. Жолинский, Т. В. Демьянова — 1990
• Hypercholesterolemia and atherosclerosis: Present and future therapy including LDL‐apheresisSusanne Bødker — 1988
• The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial: to believe or not to believe?Stephen J. Nicholls — 2012
• Cholesterol lowering does have a role in secondary prevention.Tim Van Hoolst — 1995
• The effects of lowering serum cholesterol on coronary heart disease risk.William J. Bolduc — 1994
• The prevention of cardiovascular disease. Emphasis on secondary prevention.Bgh — 1994
• Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for TreatmentGordon Schectman, Jan Hiatt — 1996
• Current concepts in secondary prevention after acute myocardial infarctionШустов Владимир Геннадьевич — 2000
• Nanette Kass Wenger, MD: a conversation with the editor [interviewed by William Clifford Roberts].Masoud Sanei, N. Noori, Hilda Saleh — 2003
• Bedeutung der Lipidtherapie bei DiabetesChristoph H. Saely, Heinz Drexel — 2010
• Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation.Daniel J. Rader, Sylvia E. Rosas — 2000
• Niacin and CarcinogenesisWoo‐Sik Jung — 2003
• High-density lipoprotein cholesterol therapies: the next frontier in lipid management.Danielle Duffy, Daniel J. Rader — 2006
• Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.Pamela Patterson Pugliese, Donald R. Chipley — 2007
• Dietary prevention of coronary artery disease. How to help patients modify eating habits and reduce cholesterol.James H. O’Keefe, Carl J. Lavie, Joan O. O'Keefe — 1989
• Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.Walter. Hallstein — 2009
• Revisiting niacin: reviewing the evidence.Sylvain Reed — 2007
• Metabolic syndrome: nature, therapeutic solutions and optionsMaria Eugenia Recalde de Payan — 2011
• A Clinician's Guide to the ABCs of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts InitiativePedro Martín Ruiz — 2013

Related papers

• Abstract and Niacin OverviewHaseeb Jafri, Richard H. Karas, Jeffrey T. Kuvin — 2009
• A case for immediate-release niacin.Mayer Bassan — 2012
• Understanding niacin formulations.John A. Pieper — 2002
• Does nicotinic acid (niacin) lower blood pressure?Harold Bays, Daniel J. Rader — 2009
• What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?Harold Bays, Christie M. Ballantyne — 2009
• Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacinY. Henkin — 1990
• Abstract and IntroductionHarold Bays, Daniel J. Rader — 2009
• Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort studyMia‐Louise Nielsen, T. C. Petersen, Julia‐Tatjana Maul — 2023
• Analysis of Factors Influencing Discontinuation of Treatment and Development of Adverse Events with Sorafenib in Patients with Advanced Hepatocellular CarcinomaAya Shimogai, Masahide Fukudo, Sachio Fukatsu — 2011
• Safety of Placebo Controls in Pediatric Hypertension TrialsP. Brian Smith, Jennifer S. Li, M. Dianne Murphy — 2008